...
首页> 外文期刊>Revista Paulista de Pediatria >UNUSUAL WARFARIN DOSE TO ACHIEVE THERAPEUTIC INR IN A 4-MONTH OLD CHILD: NON-GENETICS RISK FACTORS ARE STILL A CHALLENGE
【24h】

UNUSUAL WARFARIN DOSE TO ACHIEVE THERAPEUTIC INR IN A 4-MONTH OLD CHILD: NON-GENETICS RISK FACTORS ARE STILL A CHALLENGE

机译:在四个月大的儿童中服用非常规的华法林剂量可达到治疗性INR:非遗传风险因素仍然是一个挑战

获取原文

摘要

ABSTRACT Objective: To report a case of a 4-month old girl that required 0.7 mg/kg/day (5 mg) of warfarin and discuss relevant risk factors for requiring higher doses. Case Description: In November 2015, a 5 kg female infant (36-week preterm) was admitted to the hospital due to status epilepticus and fever. Diazepam, phenytoin and ceftriaxone were prescribed. Cerebrospinal fluid contained 7 leukocytes, 150 mg/dL proteins, 1 mg/dL glucose and gram positive cocci were observed. Cranial tomography suggested hypodense signs in the cerebellum, right temporal lobe and left basal nuclei, which was consistent with pneumococcal meningitis-induced infectious vasculitis. She required low molecular weight heparin and warfarin for post-encephalitis thrombosis. About 10 days were required to achieve therapeutic INR, and warfarin was adjusted five times since the initial prescription. Comments: The risk factors for higher warfarin doses were age and enteral tube feeding. Phenobarbital and prednisone might also have contributed with one of the highest warfarin dose ever reported. Despite current importance given to genetics testing, clinicians should attempt to identify common contributing factors for prolonged non-therapeutic INR, to minimize the risk of coagulation, and to reduce costs of hospital stay and laboratory exams.
机译:摘要目的:报告一名需要0.7 mg / kg /天(5 mg)华法林的4个月大女孩的病例,并讨论需要更高剂量的相关危险因素。病例描述:2015年11月,一名5公斤的女婴(早产36周)因癫痫持续状态和发烧入院。处方地西p,苯妥英钠和头孢曲松。脑脊液中含有7个白细胞,150 mg / dL蛋白,1 mg / dL葡萄糖和革兰氏阳性球菌。颅骨断层扫描提示小脑,右颞叶和左基底核出现低密度体征,这与肺炎球菌脑膜炎引起的感染性血管炎一致。她需要低分子量肝素和华法林治疗脑炎后血栓形成。达到治疗性INR大约需要10天,并且华法林自初始处方后已调整了5次。评论:华法林剂量较高的危险因素是年龄和肠管饲喂。苯巴比妥和泼尼松可能也是华法林有史以来报道的最高剂量之一。尽管目前对基因测试的重视,临床医生仍应尝试找出延长非治疗性INR的常见因素,以最大程度地降低凝血风险,并减少住院和实验室检查的费用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号